
GERMANY - Bridgepoint acquires Dragenopharm
Bridgepoint has acquired a majority stake in generic drugs contract manufacturer Dragenopharm Apotheker Püschl GmbH for an undisclosed amount.
The company is headquartered in Tittmoning, Bavaria, and specialises in the production and packaging of solid dosage form and coating of tablets. Dragenopharm operates four manufacturing sites in Germany and currently has a portfolio of more than 1000 different products. In 2006 it is estimated to have produced more than five billion tablets, resulting in sales of approximately EUR 68m.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater
Back to Top